NVG-291 in Spinal Cord Injury Subjects

NCT05965700 ↗

Phase 1/2 Completed 24 enrolled NervGen Pharma

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects

Timeline

Start: 2023-08-08
Primary completion: 2025-12-31
Completion: 2026-01-21

Outcome

Met primary endpoint

release “Topline data from the chronic cohort (1-10 years post-injury) of this trial showed that NVG-291 met a primary endpoint” nervgen.com ↗

release “positive topline results from the Phase 1b/2a CONNECT SCI study in chronic tetraplegia (1-10 years post-injury). NVG-291 met its primary endpoint” nervgen.com ↗

Publications

Hosseini SM, Stecina K, Nemati S, Wang RR, Zhang JV, Karimi-Abdolrezaee S. Circuit Reconstruction after Traumatic Spinal Cord Injury by Cellular and Pharmacological Approaches. J Neurosci. 2025 Aug 27;45(35):e0362252025. doi: 10.1523/JNEUROSCI.0362-25.2025.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NVG-291	Unknown	—	Subcutaneous